Speaker Profile
Ph.D., Professor, Mayo
Biography
Dr. Vemuri is a Professor in the Department of Radiology, Mayo Clinic Rochester and an imaging researcher in the population based sample of Mayo Clinic Study of Aging. She has a broad background in engineering and clinical neuroscience, with specific training and expertise in imaging of neurodegenerative disorders. Her areas of research are 1) Investigating mechanisms through which protective and risk factors influence AD imaging biomarkers and outcomes and 2) Developing and validating imaging-based biomarkers to improve the understanding and management of Alzheimer's disease and cerebrovascular disease.
Dr. Vemuri has over 170 peer-reviewed journal articles and numerous conference abstracts and book chapters to her credit. Her research work is supported by the National Institutes of Health (NIA and NINDS). She also leads MRI cores for large multi-center clinical studies on stroke (DISCOVERY) and Alzheimer’s disease (LEADS and US POINTER). She is the Chair of a large international professional area interest group on Reserve, Resilience, and Protective Factors and serves on several national and international committees including NIH study sections in her research area. Dr. Vemuri is recipient of the NIH K99/R00 Pathway to Independence grant from the NIA and was awarded the 2020 de Leon Prize in Neuroimaging in the Senior Scientist category.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
